Pharma BD Deal Intelligence
Genmab acquired ProfoundBio for $1.8 billion in an all-cash transaction (announced April 3, 2024; closed May 21, 2024), gaining rinatabart sesutecan (Rina-S), an FRalpha-targeted Topo1-inhibitor ADC, plus ProfoundBio's ADC platform and earlier candidates. Since the acquisition the asset has materially de-risked: Rina-S advanced from Phase 1/2 at deal to a broad late-stage program, securing FDA Breakthrough Therapy Designation in recurrent/progressive endometrial cancer (August 2025) on top of its January 2024 Fast Track in FRalpha-expressing platinum-resistant ovarian cancer. The pivotal Phase 3 RAINFOL-02 trial in 2L+ platinum-resistant ovarian cancer completed enrollment in March 2026, and Genmab now names Rina-S among its core late-stage launch-readiness assets alongside EPKINLY and petosemtamab, with three active Phase 3 trials (2L+ PROC, 2L PSOC maintenance, 2L+ endometrial) plus a Phase 2 NSCLC study.